Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers Sells 1,637 Shares

Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers sold 1,637 shares of Enfusion stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.53, for a total transaction of $17,237.61. Following the sale, the director now directly owns 41,675 shares of the company’s stock, valued at $438,837.75. This represents a 3.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Enfusion Trading Up 0.9 %

ENFN opened at $11.06 on Friday. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 276.44, a PEG ratio of 1.58 and a beta of 0.95. Enfusion, Inc. has a 12 month low of $7.52 and a 12 month high of $11.38. The stock has a fifty day moving average price of $10.28 and a 200-day moving average price of $9.28.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Piper Sandler lifted their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Enfusion presently has a consensus rating of “Hold” and an average price target of $10.25.

Hedge Funds Weigh In On Enfusion

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System bought a new stake in shares of Enfusion in the 2nd quarter valued at about $86,000. Harbor Capital Advisors Inc. boosted its stake in Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new position in Enfusion in the third quarter worth $114,000. Paloma Partners Management Co acquired a new position in shares of Enfusion during the third quarter worth $157,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.